NCT02732938: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients |
|
|
| Terminated | 1b/2 | 22 | US | PF-04136309, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar | Pfizer | Metastatic Pancreatic Ductal Adenocarcinoma | 09/17 | 10/17 | | |
